Noveltreat Patient Profile Matcher

Noveltreat — Patient Profile Matcher (Obesity, semaglutide 2.4 mg)

How to Use

1. Read the patient's description (age, sex, BMI, HbA1c, comorbidities, current therapy).
2. Match to one of the 7 profiles below — pick the profile whose dominant feature matches.
3. Return: anchor trial + key numbers + clinical concerns + why Noveltreat fits.
4. If the patient fits > 1 profile, list each in priority order and name the primary driver.

Profile 1 — Obese patient seeking medically-supervised weight loss

• Typical patient: BMI ≥ 30 (or ≥ 27 + comorbidity), no T2DM, failed diet/exercise alone, no prior anti-obesity pharmacotherapy.
• Concerns: weight beyond what diet/exercise achieves; sustained weight + waist reduction; safe long-term pharmacotherapy.
• Anchor trials: STEP 1, 3, 4, 5.
• Key numbers:
  • Weight: −14.9 to −17.4 % at 68 weeks (STEP 4)
  • 69.1 % ≥ 10 % loss; 50.5 % ≥ 15 % loss
  • Waist circumference: −14.6 cm
  • STEP 5 (104 weeks): sustained −15.2 %, 77.1 % with ≥ 5 % loss
  • STEP 4 withdrawal: continued semaglutide −7.9 % vs placebo +6.9 %
• Why Noveltreat: central appetite suppression, durable loss to 2 years, improved cardiometabolic risk, simple once-weekly dosing.

Profile 2 — Obese patient with uncontrolled T2DM

• Typical patient: BMI ~ 31, HbA1c ~ 7.8 %, on metformin ± SGLT2, persistent hyperglycemia and weight issues.
• Concerns: glycemic gap, weight persistence, long-term cardiometabolic risk, adherence.
• Anchor trial: STEP 2.
• Key numbers:
  • Weight: −9.6 % (vs −3.4 % placebo; p < 0.0001)
  • HbA1c: −1.6 % (from 8.1 %)
  • 68.8 % achieved ≥ 5 % weight loss
• Why Noveltreat: meaningful HbA1c reduction alongside weight loss; RSSDI / ADA endorse GLP-1 RA escalation when HbA1c 7–9 % on dual/dual+ with persistent weight issues; high compliance.

Profile 3 — Obese patient with established CVD and/or HFpEF risk

• Typical patient: BMI ~ 33, prior MI, high HFpEF risk, dyslipidemia/HTN/prediabetes.
• Concerns: recurrent CV risk, HFpEF progression, functional capacity, disease-modifying therapy.
• Anchor trials: SELECT, STEP-HFpEF (obesity + T2DM), STEP-HFpEF (no DM), STEP 5.
• Key numbers:
  • MACE ↓ 20 % over 39 months vs placebo (SELECT)
  • Weight: −8.51 %; CRP −43.5 %
  • 6-minute walk distance: +21.5 m
  • KCCQ-CSS: +16.6 points (vs +8.7 placebo); 32.3 % achieved ≥ 15-point improvement at week 52
  • STEP 5: 77.1 % ≥ 5 % weight loss at week 104
• Why Noveltreat: CV benefit independent of T2DM; improved HFpEF symptoms, physical function, QoL; addresses weight + inflammation + CV risk simultaneously; aligned with ACC 2025 / ESC guidelines.

Profile 4 — Obese patient with knee osteoarthritis

• Typical patient: BMI ~ 34, chronic knee pain, limited mobility, unable to exercise adequately.
• Concerns: meaningful weight loss despite exercise limitation, reduction in pain and functional impairment, long-term adherence.
• Anchor trial: STEP 9.
• Key numbers:
  • Weight: −13.7 % (vs −3.2 % placebo) at 68 weeks
  • WOMAC pain score: −41.7 points (vs −27.5 placebo); > 50 % achieved ≥ 41.2-point improvement
  • SF-36 physical function: +12 points (vs +6.5 placebo)
• Why Noveltreat: substantial weight loss reduces mechanical knee stress; improves physical function and mobility scores; enables gradual re-engagement in activity; once-weekly simplicity.

Profile 5 — Obese patient with MASH (metabolic dysfunction-associated steatohepatitis)

• Typical patient: BMI ~ 31, F2 fibrosis, prediabetes (HbA1c ~ 6.4 %), metabolic syndrome, on metformin ± pioglitazone.
• Concerns: halting fibrosis, steatohepatitis resolution, safe option in multi-morbid patient.
• Anchor trial: ESSENCE (interim analysis at week 72).
• Key numbers:
  • Fibrosis reduction: 36.8 % (vs 22.4 % placebo)
  • MASH resolution without fibrosis worsening: 62.9 % (vs 34.3 %); absolute difference 28.7 %, p < 0.001
  • Combined steatohepatitis resolution + fibrosis reduction: 32.7 % (vs 16.1 %); absolute difference 14.4 %, p < 0.001
  • Weight: −10.5 %
• Why Noveltreat: currently the only FDA-approved glucose-lowering / obesity medication for MASH; improves insulin resistance, liver inflammation, cardiometabolic markers; low hypoglycemia risk.

Profile 6 — Obese patient with prediabetes

• Typical patient: BMI ~ 32, HbA1c ~ 6.1 %, FPG ~ 110 mg/dL, Class I obesity, mild dyslipidemia/HTN.
• Concerns: effective weight loss beyond lifestyle, prevention-focused intervention, adherence.
• Anchor trial: STEP 10.
• Key numbers:
  • 81 % reversion to normoglycemia (vs 14 % placebo)
  • Weight: −13.9 % (vs −2.7 % placebo)
• Why Noveltreat: produces substantial sustained weight loss > 10 %; improves insulin sensitivity; facilitates reversion from prediabetes to normoglycemia.

Profile 7 — Obese patient with PCOS

• Typical patient: BMI ~ 33, irregular / oligomenorrhoeic cycles, insulin-resistant, ≥ 6 months of structured lifestyle with inadequate response, on metformin.
• Concerns: sustained weight loss, insulin resistance, menstrual regularity, hyperandrogenism, fertility goals.
• Anchor trials: STEP 1, STEP 5, and obesity-PCOS study (semaglutide 0.5 mg SC, 3 months).
• Key numbers:
  • PCOS study: mean weight −7.6 kg, BMI −3.1 kg/m², −8.9 % body weight at 3 months
  • 80 % of patients on 0.5 mg semaglutide had regular menstrual cycles
  • STEP 1: 32 % achieved ≥ 20 % weight loss at 68 weeks
  • STEP 5: 36.1 % ≥ 20 % loss at 104 weeks; fasting insulin −32.7 % vs −7.2 % placebo
• Why Noveltreat: meaningful sustained weight loss is central to improving PCOS pathophysiology; helps maintain loss long-term; improves waist circumference, metabolic and inflammatory markers.

Output Template

When returning a match, use this structure:

Best-fit profile: <n>. <profile name>
Anchor trial(s): <trial names>
Expected outcomes: <key numbers for this profile>
Why Noveltreat fits: <3–5 bullet rationale>
Caveats: <relevant contraindications or monitoring>
→ Dose and start: see `noveltreat-prescribing-guide`

If the patient has T2DM + CKD instead of obesity focus, note that Noveltreat is the obesity brand — Sematrinity is the T2DM brand; recommend checking the companion T2DM profile sheet.

Reference

Sun Pharmaceutical Industries Ltd. Product Monograph — Diabetes and Obesity (Sematrinity® and Noveltreat®), 2026 (Data on file).